Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2

Por Gabriel N. Hortobagyi
Publicado em 2015-03-01

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Por Zhou Jiang, Jennifer L. Hsu, Yintao Li, Gabriel N. Hortobagyi, Mien-Chie Hung, Mien-Chie Hung, Mien-Chie Hung
Publicado em 2020-07-01

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial

Por Xiaotong Li, Sarah Warren, Vasiliki Pelekanou, Vikram Wali, Alessandra Cesano, Mingdong Liu, Patrick Danaher, Nathane Elliott, Zeina A. Nahleh, Daniel F. Hayes, Gabriel N. Hortobagyi, William E. Barlow, Christos Hatzis, Lajos Pusztai
Publicado em 2019-04-01

High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast canc...

Por Simone Anfossi, Antonio Giordano, Hui Gao, Evan N Cohen, Sanda Tin, Qiong Wu, Raul J Garza, Bisrat G Debeb, Ricardo H Alvarez, Vicente Valero, Gabriel N Hortobagyi, George A Calin, Naoto T Ueno, Wendy A Woodward, James M Reuben
Publicado em 2014-01-01